MedTrace Logo

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

NCT05724329 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-09-19

No results posted yet for this study

Summary

The trial is being conducted to evaluate the efficacy and safety of Tislelizumab in combination with dasatinib and quercetin(combining immunotherapy and senolytics, COIS) in patients with head and neck squamous cell carcinoma who are about to undergo surgery.

Conditions

  • Head and Neck Squamous Cell Carcinomas

Interventions

DRUG

Tislelizumab + Dasatinib + Quercetin (neoadjuvant)

Patients receive Tislelizumab (IV) on day 1, dasatinib (PO) on day 1,2,3 and quercetin (PO) on day 1,2,3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

PROCEDURE

surgery

Standard of care

DRUG

Tislelizumab + Dasatinib + Quercetin (adjuvant)

Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10

Sponsors & Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-05
Primary Completion
2024-04-05
Completion
2028-08-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05724329 on ClinicalTrials.gov